MedPath

Feasibility and Evaluation Study of the UPLUG Hemodialysis Connection Device

Not Applicable
Completed
Conditions
Hemodialysis
Renal Insufficiency, Chronic
Registration Number
NCT05419258
Lead Sponsor
University Hospital, Caen
Brief Summary

The new Uplug° technology, interface between the end of the hemodialysis catheter and the dialysis circuit, makes it possible to limit direct access to the hemodialysis catheter during connections and disconnections.

Aim:

The investigators propose a feasibility study, in order to study the new Uplug° technology in real conditions of use.

Material and methods:

This study aim to include 15 hemodialysis patients in a center on a tunneled permanent central venous hemodialysis catheter. The Uplug° technology will be placed at the end of each patient's hemodialysis catheter for a period of one month.

Hypothesis tested:

The main endpoint is the proportion of hemodialysis sessions performed successfully with this technology, respecting the usual dialysis prescription.

Detailed Description

The incidence and prevalence of chronic insufficiency have been growing for several years. Increasingly older patients are treated with chronic hemodialysis. The vascular access of choice remains the arteriovenous fistula and the proportion of hemodialysis patients on the permanent central venous hemodialysis catheter varies from 20 to 35% in dialysis centres. The new Uplug° technology, interface between the end of the hemodialysis catheter and the dialysis circuit, makes it possible to limit direct access to the hemodialysis catheter during connections and disconnections.

Aim:

The investigators propose a feasibility study, in order to study the new Uplug° technology in real conditions of use.

Material and methods:

This study aim to include 15 hemodialysis patients in a center on a tunneled permanent central venous hemodialysis catheter. The inclusion period is three months. The follow-up time for each participant is 6 weeks. Patients with a tunneled permanent central venous hemodialysis catheter and performing dialysis sessions with a flow rate ≥ 300 ml/min may be included. The Uplug° technology will be placed at the end of each patient's hemodialysis catheter for a period of one month.

Hypothesis tested:

The main endpoint is the proportion of hemodialysis sessions performed successfully with this technology, respecting the usual dialysis prescription.

The secondary objectives are the infectious risk, the defects of the experimental device and the hemodialysis catheter or their implementation, the satisfaction of the nursing staff and the patient, the reduction in the number of manipulations and the effective time of these manipulations.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
15
Inclusion Criteria
  • with end-stage chronic renal failure treated by hemodialysis (2 or 3 sessions per week)
  • Wearer of a right or left jugular permanent tunneled central venous hemodialysis catheter whose end has been in the superior vena cava or the right atrium for at least 1 month
  • Hemodialysis catheter lock used = heparin or 4% citrate
  • Expected life expectancy > 6 months
  • Dialysis session preceding inclusion with an average blood flow of at least 300ml/min
Exclusion Criteria
  • Patient with a mechanical heart valve
  • Patient with an arteriovenous fistula (AVF) that can be used within one month
  • Kidney transplant by living donor planned in the following month
  • Pregnant or breastfeeding woman
  • History of infection on the hemodialysis catheter in place dating from less than 6 months
  • Psychiatric or demented patient unable to obtain informed consent
  • Patient already included in another protocol

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
success in performing dialysisone month

Study the feasibility of performing dialysis with the UPlug Technology in patients with a permanent tunneled central venous hemodialysis catheter with the objective of a success rate ≥ 80%.

Secondary Outcome Measures
NameTimeMethod
Number of participants with Adverse Events [Safety and Tolerability] of the experimental device UPLUGone month

adverse events reported from consent to end of study

patient satisfactionone month

satisfaction evaluated by questionnaire before and after the use of experimental device

experimental device integrityone month

device deficiencies reported from consent to end of study

clinical performance of deviceone month

performance measured by rate of successful sessions

nurses' satisfactionone month

satisfaction evaluated by questionnaire before and after the inclusions

Trial Locations

Locations (1)

CHU Caen Normandie

🇫🇷

Caen, France

CHU Caen Normandie
🇫🇷Caen, France

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.